EUVIMEDEUVIMED entdecken
Crossref

Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies

Madeline D Schultze, David J Reeves iD

Annals of Pharmacotherapy · 2024

DOI: 10.1177/10600280231223737 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Madeline D Schultze und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy & Health Sciences, Butler University, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective was to evaluate the efficacy/safety of pirtobrutinib in the treatment of B-cell malignancies and distinguish it from other available Bruton’s tyrosine kinase (BTK) inhibitors. Data sources: A literature search of PubMed (January 2021 through November 2023) and Clinicaltrials.gov was conducted using terms pirtobrutinib, Jaypirca, and LOXO 305. Licensing trials of available BTK inhibitors were also reviewed. Study selection and data extraction: Relevant English-language clinical trials were evaluated. Data synthesis: Pirtobrutinib was approved by the US Food and Drug Administration for the treatment of relapsed/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) based largely on a phase 1/2 study in B-cell malignancies. Pirtobrutinib demonstrated a 73% overall response rate (ORR) in the CLL population and 58% in MCL. Pirtobrutinib has activity in patients resistant to earlier-generation, covalent BTK inhibitors. In fact, the ORRs were similar in BTK-pretreated and naïve patients. Adverse effects include fatigue, diarrhea, bleeding, and infection. Atrial fibrillation, a class effect of BTK inhibitors, may be less common with pirtobrutinib. Relevance to patient care and clinical practice in comparison with existing drugs: Compared with earlier-generation BTK inhibitors, pirtobrutinib is more selective for BTK and binds noncovalently to the receptor. Ongoing studies are evaluating pirtobrutinib’s use in multiple B-cell malignancies and comparing it with other BTK inhibitors.

Conclusion

The characteristics of pirtobrutinib render it useful in the treatment of B-cell malignancies no longer responding to a previous BTK inhibitor, and results from ongoing clinical trials may support future expanded use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Agammaglobulinaemia Tyrosine KinaseLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-CellProtein Kinase InhibitorsPyrazolesHumansAntineoplastic Agents

Stichwörter der Autor:innen

adverse drug reactionscancerclinical pharmacologydrug interactionshematologyleukemiapharmacodynamics

Substanzen

Agammaglobulinaemia Tyrosine KinaseAntineoplastic AgentsBTK protein, humanpirtobrutinibProtein Kinase InhibitorsPyrazoles

Autor:innen und Institutionen

  • College of Pharmacy & Health Sciences, Butler University, Indianapolis, IN, USA.
  • Franciscan Health Indianapolis, IN, USA.

ORCID-Profile: David J Reeves

Zitieren

APA

Schultze, M. D., & Reeves, D. J. (2024). Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231223737

Vancouver

Schultze MD, Reeves DJ. Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231223737

BibTeX
@article{Schultze2024,
  author = {Schultze, Madeline D and Reeves, David J},
  title = {Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies},
  journal = {Annals of Pharmacotherapy},
  year = {2024},
  doi = {10.1177/10600280231223737}
}
Kostenlos starten →